R&D

Codexis in Protein R&D Pact with Tate & Lyle

Astellas Pays €800 Million for Ogeda

Merck and Avillion in Psoriasis Pact

DuPont Informs Ag Employees on Sell-offs

GSK and Regeneron Back UK Biobank Project

EU Commission Greenlights DowDuPont

MRC Licenses Hepatitis C Antibody to China

Allergan and Editas Medicine in Eye Disease Pact

Envigo Creates Non-animal Cardiac Tests

BASF Inaugurates Indian Innovation Campus

Lianhetech Enters Europe with Fine Industries Buy

MEPs Take on EU Drug Pricing

Cancer Research UK and HitGen in Pact

FDA Accepts Merck-Pfizer Biologics Application

Confidence in Agriculture Mergers Solidifies

A Visible Turning Point for Oxea

Ten years ago, in March 2007, oxo chemicals producer Oxea was established as a buyout led by private-equity firm Advent International of oxo derivatives and oxo intermediates businesses from Celanese and European Oxo.

Solvay Takes DuPont’s Energain Li-Ion Technology

Novo Nordisk Invests in UK Research Center

BASF Enters Indian Rice Crop Protection Market

DowDuPont Closing Pushed into Q2

Bayer Promises Trump $8 Billion for US Research?

Takeda to Take Ariad for $5.2 Billion

J&J and Actelion Said Talking to Swiss Regulators

Shire Sells MRT to RaNA Therapeutics

Vencorex Expands Global Isocyanates

Sanofi and MSD End Vaccines JV

J&J Deal Could Split Actelion

Pfizer and IBM in e-Health Alliance

Lenzing Plans US Tencel Plant

Kansai Paint Acquires Helios Coatings

Lonza Confirms Talks With Capsugel

Dow CEO Liveris and Trump Display Unity

Slovakia’s Saneca Gets Grant to Boost R&D

The Winning Formula

Boehringer in China R&D Pact, Job Cut Plans